|
|
Article: NEOPHARM Announces Presentation of Final Safety Data from Phase 1 Trial of CINTREDEKIN BESUDOTOX for Newly Diagnosed Malignant Glioma.
- Article from:
- Business Wire
- Article date:
- November 20, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Phase 2 Trial Expected To Begin In The First Half Of 2007
WAUKEGAN, Ill. -- NEOPHARM, Inc. (Nasdaq:NEOL) today announced the presentation of final Phase 1 safety results at the Society for Neuro-Oncology (SNO) 11th Annual Meeting in Orlando, FL. Data from this 22 patient trial showed that 0.5 g/mL of CINTREDEKIN BESUDOTOX delivered via Convection-Enhanced Delivery (CED) followed by external beam radiation therapy (EBRT) with or without concurrent temozolomide following tumor resection appears to be safe and well-tolerated in patients with newly diagnosed malignant glioma.
"This safety data is very encouraging and supports the potential for CINTREDEKIN ...